Anavex Life Sciences Corp (AVXL)

[falconer66a]

My numbers, too.

With a conservative PE ratio of just 20, then that would equate to conservatively $1600 per share for AVXL.

George, thank you. These are exactly the same numbers I’ve punched into my AVXL values spreadsheet. Like yourself, I prefer to work with conservative numbers, both as to actual numbers of patients taking blarcamesine, and as to the price of daily treatment dosages. Ten dollars works fine.

But those familiar with spreadsheets know that one can easily punch up new pages, with new, different numbers. Hit the Enter key and everything instantly works out, appears.

I’ve done that for the (presently) two other CNS disease blarcamesine will eventually treat. For Rett syndrome, the numbers are only in the tens of millions. But add in Parkinson’s disease, things get very big, on top of the gigantic Alzheimer’s metrics.

Of course, we are projecting numbers for only American patients. All of Europe is a potential market, equal or larger than the U.S. Considering things globally, our numbers double or triple.

Then, of course, when it’s discovered that daily dosings of blarcamesine are prophylactic, for Parkinson’s and Alzheimer’s in particular, and many other geriatric diseases in general, governmental policy makers will use their own spreadsheets to calculate the health care cost savings if blarcamesine might significantly reduce those requiring government assistance dealing with Parkinson’s and Alzheimer’s. What happens when everyone, at age 40 or 50, starts taking blarcamesine?

As they have, as they will, many laugh at our projected $1600 AVXL share prices. In five years (or less), let’s see who’s laughing; who will be able to laugh, instead of being holed up in an Alzheimer’s care center, slowing dying.